In vivo environment necessary to support transplanted donor mouse T regulatory cells

American Journal of Transplantation

Volumn 14, Issue 5, 2014, Pages 1032-1045

  Cabello Kindelan, C ^a   De La Barrera, A ^a   Malek, T R ^a   Bayer, A L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; T cells; T regulatory cells; tolerance; transplantation

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL; AUTOIMMUNITY; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DONOR; FEMALE; GRAFT REJECTION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MALE; METABOLISM; MOUSE; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; SKIN DISEASES; SKIN TRANSPLANTATION; TRANSGENIC MOUSE; TRANSPLANTATION TOLERANCE;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT REJECTION; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; SKIN DISEASES; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; TRANSPLANTATION TOLERANCE;

EID: 84899452544     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12650     Document Type: Article

References (56)

1. Gorantla VS, Schneeberger S, Brandacher G, et al. T regulatory cells and transplantation tolerance. Transplant Rev (Orlando) 2010; 24: 147-159.
2. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H., Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002; 168: 5558-5565.
3. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166: 3789-3796.
4. Johnson BD, Konkol MC, Truitt RL., CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. Biol Blood Marrow Transplant 2002; 8: 525-535.
5. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080-1086.
6. Taylor PA, Lees CJ, Blazar BR., The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493-3499.
7. + T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004; 104: 3804-3812.
8. Marek-Trzonkowska N, Mysliwec M, Siebert J, Trzonkowski P., Clinical application of regulatory T cells in type 1 diabetes. Pediatr Diabetes 2013; 14: 322-332.
9. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Administration of CD4+ CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children. Diabetes Care 2012; 35: 1817-1820.
10. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009; 58: 652-662.
11. Trzonkowski P, Szarynska M, Mysliwska J, Mysliwski A., Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A 2009; 75: 175-188.
12. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
13. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-3928.
14. Roncarolo MG, Gregori S, Lucarelli B, Ciceri F, Bacchetta R., Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev 2011; 241: 145-163.
15. + T regulatory cells. J Immunol 2008; 181: 225-234.
16. + T regulatory cell development during the neonatal period. J Exp Med 2005; 201: 769-777.
17. + T regulatory cells. J Immunol 2007; 178: 4062-4071.
18. + regulatory T cells. J Immunol 2007; 178: 280-290.
19. Malek TR, Yu A, Vincek V, Scibelli P, Kong L., CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002; 17: 167-178.
20. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C., Regulatory CD4 T cells: Expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998; 10: 371-378.
21. + regulatory T cells. Nat Immunol 2003; 4: 330-336.
22. Hori S, Nomura T, Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
23. + T regulatory cells suppress autoimmunity while establishing transplantation tolerance. J Immunol 2006; 176: 7149-7153.
24. + T lymphocytes. Blood 2004; 103: 4216-4221.
25. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+ CD25+ Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88-92.
26. Porter BO, Scibelli P, Malek TR., Control of T cell development in vivo by subdomains within the IL-7 receptor alpha-chain cytoplasmic tail. J Immunol 2001; 166: 262-269.
27. Billingham RE, Medawar PB., The technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385-402.
28. + regulatory T cells. J Immunol 2003; 171: 3348-3352.
29. reg compartment after experimental HCT. Blood 2009; 113: 733-743.
30. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C., IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007; 110: 3192-3201.
31. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112: 610-618.
32. Brode S, Raine T, Zaccone P, Cooke A., Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+ CD25+ Foxp3+ regulatory T cells. J Immunol 2006; 177: 6603-6612.
33. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H., Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
34. + regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6: 1152-1159.
35. Xia J, Liu W, Hu B, Tian Z, Yang Y., IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice. Clin Immunol 2010; 134: 130-139.
36. He YW, Malek TR., The structure and function of gamma c-dependent cytokines and receptors: Regulation of T lymphocyte development and homeostasis. Crit Rev Immunol 1998; 18: 503-524.
37. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-8347.
38. + regulatory T cells. Blood 2005; 105: 4743-4748.
39. + regulatory T-cells. Diabetes 2008; 57: 2341-2347.
40. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY., A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-1151.
41. Abdul-Hai A, Ben-Yehuda A, Galsky H, Slavin S, Or R., Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice. Cancer Immunol Immunother 2006; 55: 1330-1336.
42. Chik KW, Li K, Pong H, Shing MM, Li CK, Yuen PM., Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation. J Pediatr Hematol Oncol 2003; 25: 960-964.
43. Cooley MA, Wright L, Atkinson K., Cytokine activity after allogeneic bone marrow transplantation. V. Analysis of IL-2 and IFN production by isolated CD4+ and CD8+ cells. Br J Haematol 1994; 86: 702-708.
44. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202: 907-912.
45. Goldrath AW, Sivakumar PV, Glaccum M, et al. Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med 2002; 195: 1515-1522.
46. Surh CD, Sprent J., Homeostasis of naive and memory T cells. Immunity 2008; 29: 848-862.
47. Tan JT, Ernst B, Kieper WC, LeRoy E, Sprent J, Surh CD., Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J Exp Med 2002; 195: 1523-1532.
48. Bayer AL, Chirinos J, Cabello C, et al. Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation. Eur J Immunol 2011; 41: 3467-3478.
49. Yu A, Zhu L, Altman NH, Malek TR., A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009; 30: 204-217.
50. Graca L, Cobbold SP, Waldmann H., Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641-1646.
51. Adeegbe D, Levy RB, Malek TR., Allogeneic T regulatory cell-mediated transplantation tolerance in adoptive therapy depends on dominant peripheral suppression and central tolerance. Blood 2010; 115: 1932-1940.
52. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK., Response to self antigen imprints regulatory memory in tissues. Nature 2011; 480: 538-542.
53. Pilat N, Baranyi U, Klaus C, et al. Treg-therapy allows mixed chimerism and transplantation tolerance without cytoreductive conditioning. Am J Transplant 2010; 10: 751-762.
54. Gitelman SE, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013; 1: 306-316.
55. Herold KC, Gitelman S, Greenbaum C, et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132: 166-173.
56. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378: 487-497.